Proteona received Seal of Excellence from Horizon 2020, European Commission
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona announced that it has been awarded the Seal of Excellence by the prestigious Horizon 2020, European Commission. The Seal of Excellence is a quality label certifying top innovation ideas worthy of investment.
“We are proud to be recognized by Horizon 2020. The Seal of Excellence confirms that Proteona is bringing strong added value, making a global impact, and has the capability to execute its business plans,” said Dr. Andreas Schmidt, CEO of Proteona.
Proteona aims to improve the clinical outcome of multiple myeloma
using personalized single cell proteogenomic analysis. Using proprietary
DNA-barcoded antibodies as well as AI-assisted algorithms, Proteona
provides comprehensive information on tumor heterogeneity, and therefore
enables clinicians and pharmaceutical companies to identify targeted therapy.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.